269 related articles for article (PubMed ID: 18678301)
21. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
Alrasadi K; Awan Z; Alwaili K; Ruel I; Hafiane A; Krimbou L; Genest J
Am J Cardiol; 2008 Nov; 102(10):1341-7. PubMed ID: 18993152
[TBL] [Abstract][Full Text] [Related]
22. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
Vrablík M; Dobiásová M; Stulc T; Kasalová Z; Dolezalová R; Prázný M; Fait T; Ceska R
Neuro Endocrinol Lett; 2008 Feb; 29(1):146-50. PubMed ID: 18283261
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.
Koanantakul B; Jeamanukulkit N; Piamsomboon C; Chawantanpipat C; Khanacharoen I
J Med Assoc Thai; 2004 Nov; 87(11):1281-5. PubMed ID: 15825700
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.
Farnier M; Freeman MW; Macdonell G; Perevozskaya I; Davies MJ; Mitchel YB; Gumbiner B;
Eur Heart J; 2005 May; 26(9):897-905. PubMed ID: 15781429
[TBL] [Abstract][Full Text] [Related]
25. Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic acid (LY518674), that produces marked changes in serum lipids and apolipoprotein A-1 expression.
Singh JP; Kauffman R; Bensch W; Wang G; McClelland P; Bean J; Montrose C; Mantlo N; Wagle A
Mol Pharmacol; 2005 Sep; 68(3):763-8. PubMed ID: 15933217
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
[TBL] [Abstract][Full Text] [Related]
27. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon.
Magee G; Sharpe PC
J Clin Pathol; 2009 Mar; 62(3):250-3. PubMed ID: 19251953
[TBL] [Abstract][Full Text] [Related]
28. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
Balogh Z; Seres I; Harangi M; Kovács P; Kakuk G; Paragh G
Diabetes Metab; 2001 Nov; 27(5 Pt 1):604-10. PubMed ID: 11694861
[TBL] [Abstract][Full Text] [Related]
29. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
Maki KC; McKenney JM; Reeves MS; Lubin BC; Dicklin MR
Am J Cardiol; 2008 Aug; 102(4):429-33. PubMed ID: 18678300
[TBL] [Abstract][Full Text] [Related]
30. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
Tonelli M; Collins D; Robins S; Bloomfield H; Curhan GC
Am J Kidney Dis; 2004 Nov; 44(5):832-9. PubMed ID: 15492949
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial.
Adabag AS; Mithani S; Al Aloul B; Collins D; Bertog S; Bloomfield HE;
Am Heart J; 2009 May; 157(5):913-8. PubMed ID: 19376321
[TBL] [Abstract][Full Text] [Related]
32. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
Davidson MH; McKenney JM; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1774-81. PubMed ID: 17084249
[TBL] [Abstract][Full Text] [Related]
34. Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation.
Løvås K; Røst TH; Skorve J; Ulvik RJ; Gudbrandsen OA; Bohov P; Wensaas AJ; Rustan AC; Berge RK; Husebye ES
Diabetes Obes Metab; 2009 Apr; 11(4):304-14. PubMed ID: 19267708
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
McKenney JM; Farnier M; Lo KW; Bays HE; Perevozkaya I; Carlson G; Davies MJ; Mitchel YB; Gumbiner B
J Am Coll Cardiol; 2006 Apr; 47(8):1584-7. PubMed ID: 16630994
[TBL] [Abstract][Full Text] [Related]
36. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
[TBL] [Abstract][Full Text] [Related]
37. Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor alpha, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study.
Do HQ; Nazih H; Luc G; Arveiler D; Ferrières J; Evans A; Amouyel P; Cambien F; Ducimetière P; Bard JM
Metabolism; 2009 Mar; 58(3):283-9. PubMed ID: 19217440
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
Farnier M; Roth E; Gil-Extremera B; Mendez GF; Macdonell G; Hamlin C; Perevozskaya I; Davies MJ; Kush D; Mitchel YB;
Am Heart J; 2007 Feb; 153(2):335.e1-8. PubMed ID: 17239698
[TBL] [Abstract][Full Text] [Related]
40. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
